BMO Capital on Protagonist Therapeutics (PTGX): 'UEG Icotrokinra Full Data Remains Compelling'
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $72.00 price target on Protagonist Therapeutics (NASDAQ: PTGX).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
